Saturday, July 15, 2023 12:41:20 AM
I beg to differ.
The phase 3 trial in effect was also a trial of the entities and steps and distribution of treating over 300 patients in four countries.
The actual administration of the vaccine is easy, like a flu shot as long as the low temperature facilities are available as they were for the trial.
The tumor is obtained by the neurosurgeon and frozen just as in the trial. The tumor is shipped to Sawston (or another certified facility such as CRL in Memphis if re-engaged) and the most sensitive part of the process is where is the leukapheresis(sp?) performed? Les implied that might be best done closer to the production facility due to timing/aging of dendritic cells maturation.
So for GBM it is plausible for nwbo to go it alone imo.
The phase 3 trial in effect was also a trial of the entities and steps and distribution of treating over 300 patients in four countries.
The actual administration of the vaccine is easy, like a flu shot as long as the low temperature facilities are available as they were for the trial.
The tumor is obtained by the neurosurgeon and frozen just as in the trial. The tumor is shipped to Sawston (or another certified facility such as CRL in Memphis if re-engaged) and the most sensitive part of the process is where is the leukapheresis(sp?) performed? Les implied that might be best done closer to the production facility due to timing/aging of dendritic cells maturation.
So for GBM it is plausible for nwbo to go it alone imo.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
